BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.

被引：0
|
作者：
Hu, Xingsheng
Zheng, Xin
Mo, Hongnan
Cui, Xinge
Ding, Lieming
Tan, Fenlai
Hu, Pei
Shi, Yuankai
机构：
[1] Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticancer Mol Targete, Canc Hosp, Natl Canc Ctr, Beijing, Peoples R China
[2] Peking Union Med Coll, Beijing, Peoples R China
[3] Peking Union Med Coll Hosp, Peking Union Med Coll, Clin Pharmacol Res Ctr, Beijing, Peoples R China
[4] Chinese Acad Med Sci, Beijing, Peoples R China
[5] Peking Union Med Coll Hosp, Beijing, Peoples R China
[6] Betta Pharmaceut Co Ltd, Hangzhou, Zhejiang, Peoples R China
[7] Peking Union Med Coll Hosp, Clin Pharmacol Res Ctr, Beijing, Peoples R China
[8] Chinese Acad Med Sci, Beijing Key Lab Clin Study Anticancer Mol Targete, Canc Hosp, Dept Med Oncol,Natl Canc Ctr, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21108
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21108
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.
    Patnaik, A.
    Appleman, L. J.
    Mountz, J. M.
    Ramanathan, R. K.
    Beeram, M.
    Tolcher, A. W.
    Papadopoulos, K. P.
    Lotze, M. T.
    Petro, D. P.
    Laymon, C.
    Paige, L.
    Rajagopalan, P.
    Jeffers, M.
    Roth, D.
    Dubowy, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Simultaneous determination of a novel c-Met/AXL dual-target small-molecule inhibitor BPI-9016M and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry: Application in a pharmacokinetic study in Chinese advanced solid tumor patients
    Cui, Xinge
    Zheng, Xin
    Jiang, Ji
    Tan, Fenlai
    Ding, Lieming
    Hu, Pei
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2017, 1068 : 33 - 40
  • [33] Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors
    Bashir, Babar
    Wang, Judy S.
    Falchook, Gerald
    Fontana, Elisa
    Arkenau, Hendrik-Tobias
    Carter, Louise
    Galot, Rachel
    Basu, Bristi
    Greystoke, Alastair
    Subbiah, Vivek
    Richardson, Debra L.
    Orr, Hanna
    Bennett, Gavin
    Sharma, Rajiv
    Xu, Hongmei
    Paganoni, Paola
    Xu, Cong
    Campbell, Carly
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (29)
  • [34] First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part
    Doi, Toshihiko
    Matsubara, Nobuaki
    Naito, Yoichi
    Kuboki, Yasutoshi
    Harano, Kenichi
    Ono, Makiko
    Urasaki, Tetsuya
    Ohmoto, Akihiro
    Kawanai, Tsubasa
    Hisai, Takashi
    Ikezawa, Hiroki
    Shiba, Sari
    Ito, Ken
    Semba, Taro
    Asano, Osamu
    Takahashi, Shunji
    CANCER, 2023, 129 (15) : 2348 - 2359
  • [35] First-in-human, dose-escalation phase I trial of intratumoral (IT) CyPep-1 in patients (pts) with advanced solid tumors
    Eskens, F.
    Opdam, F.
    Gort, E.
    Gelderblom, H.
    Prestegarden, L.
    Pico-Navarro, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S758 - S758
  • [36] Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study
    Xingsheng Hu
    Xinge Cui
    Ziping Wang
    Yunpeng Liu
    Ying Luo
    Wei Zhong
    Hui Zhao
    Mengxing Yao
    Da Jiang
    Mingxia Wang
    Minjiang Chen
    Xin Zheng
    Lieming Ding
    Yang Wang
    Xiaobin Yuan
    Pengxiang Wu
    Bei Hu
    Xiaohong Han
    Yuankai Shi
    BMC Cancer, 23
  • [37] A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
    Juric, Dejan
    de Bono, Johann S.
    LoRusso, Patricia M.
    Nemunaitis, John
    Heath, Elisabeth I.
    Kwak, Eunice L.
    Macarulla Mercade, Teresa
    Geuna, Elena
    de Miguel-Luken, Maria Jose
    Patel, Chirag
    Kuida, Keisuke
    Sankoh, Serap
    Westin, Eric H.
    Zohren, Fabian
    Shou, Yaping
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5015 - 5023
  • [38] A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors.
    Doi, T.
    Murakami, H.
    Wan, K.
    Miki, M.
    Kotani, H.
    Sakamoto, N.
    Yamamoto, N.
    Ohtsu, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study
    Hu, Xingsheng
    Cui, Xinge
    Wang, Ziping
    Liu, Yunpeng
    Luo, Ying
    Zhong, Wei
    Zhao, Hui
    Yao, Mengxing
    Jiang, Da
    Wang, Mingxia
    Chen, Minjiang
    Zheng, Xin
    Ding, Lieming
    Wang, Yang
    Yuan, Xiaobin
    Wu, Pengxiang
    Hu, Bei
    Han, Xiaohong
    Shi, Yuankai
    BMC CANCER, 2023, 23 (01)
  • [40] Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.
    Fedyanin, Mikhail
    Tryakin, Alexey
    Lisyanskaya, Alla Sergeevna
    Solovyeva, Ekaterina
    Fadeeva, Natalia
    Gladkov, Oleg
    Moiseyenko, Vladimir
    Cheporov, Sergey, V
    Shpigotskaya, Polina
    Purmal, Andrei
    Miller, Langdon L.
    Leonov, Andrey
    Zakurdaeva, Kristina
    Gurova, Katerina
    Gudkov, Andrei
    Tjulandin, Sergei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345